+571.9%
HPE vs GSK
+108.0%
+463.9%
-56.9%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for all.
| Period | Portfolio | GSK | Excess | Alpha |
|---|---|---|---|---|
| 1D | -3.7% | +0.5% | -4.3% | -3.9% |
| 7D | +7.9% | +1.1% | +6.7% | +7.6% |
| 30D | -23.5% | +6.3% | -29.8% | -24.8% |
| 3M | -19.1% | +1.8% | -20.9% | -19.9% |
| 6M | +51.4% | +1.7% | +49.7% | +48.6% |
| YTD | +103.4% | +6.5% | +96.9% | +95.9% |
| 1Y | +114.4% | +9.5% | +104.9% | +104.4% |
| 3Y | +224.7% | +65.3% | +159.4% | +155.8% |
| 5Y | +277.8% | +43.7% | +234.0% | +210.1% |
| 10Y | +371.1% | +104.1% | +267.0% | +209.3% |
| All | +571.9% | +108.0% | +463.9% | +323.3% |
Cumulative growth
Daily Returns
Daily percentage return beside GSK.
Daily Out/Under-Performance
Portfolio return minus GSK return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × GSK return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over all: compounded portfolio wealth divided by compounded GSK wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
all analysis · Full analysis span regression · 6 months rolling